BTIG Research Initiates Coverage on Pyxis Oncology (NASDAQ:PYXS)

Analysts at BTIG Research began coverage on shares of Pyxis Oncology (NASDAQ:PYXSGet Free Report) in a note issued to investors on Friday, Briefing.com reports. The firm set a “buy” rating and a $8.00 price target on the stock. BTIG Research’s target price would suggest a potential upside of 115.63% from the company’s previous close.

Other analysts also recently issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Pyxis Oncology in a report on Thursday, November 30th. Leerink Partnrs restated an “outperform” rating on shares of Pyxis Oncology in a report on Tuesday, January 23rd. SVB Leerink started coverage on shares of Pyxis Oncology in a report on Tuesday, January 23rd. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, William Blair restated an “outperform” rating on shares of Pyxis Oncology in a report on Wednesday, November 8th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Pyxis Oncology has a consensus rating of “Buy” and an average target price of $9.00.

Check Out Our Latest Analysis on PYXS

Pyxis Oncology Stock Performance

Shares of NASDAQ PYXS opened at $3.71 on Friday. The company has a market cap of $164.43 million, a P/E ratio of -1.45 and a beta of 1.27. The firm’s fifty day moving average is $2.40 and its two-hundred day moving average is $2.12. Pyxis Oncology has a 52-week low of $1.35 and a 52-week high of $6.92.

Pyxis Oncology (NASDAQ:PYXSGet Free Report) last posted its earnings results on Tuesday, November 7th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.01. As a group, analysts forecast that Pyxis Oncology will post -1.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

Large investors have recently added to or reduced their stakes in the stock. Prelude Capital Management LLC purchased a new stake in Pyxis Oncology in the 2nd quarter valued at about $27,000. Tower Research Capital LLC TRC boosted its position in Pyxis Oncology by 75.9% in the 1st quarter. Tower Research Capital LLC TRC now owns 10,866 shares of the company’s stock valued at $43,000 after buying an additional 4,688 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Pyxis Oncology in the 1st quarter valued at about $48,000. Goldman Sachs Group Inc. purchased a new stake in Pyxis Oncology in the 2nd quarter valued at about $31,000. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of Pyxis Oncology in the 3rd quarter worth approximately $26,000. 52.53% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

(Get Free Report)

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.

Recommended Stories

Analyst Recommendations for Pyxis Oncology (NASDAQ:PYXS)

Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.